Antigen device

Abstract

The invention relates to an implantable device for in vivo delivery of one or more tumour-specific antigens within a patient, the device being configured to release said tumour-specific antigens local

Description

This invention relates to in-vivo antigen administering devices and methodology. Multi-antigen presenting vaccines are a type of vaccine designed to stimulate the immune system by presenting multiple antigens—substances that the immune system recognizes as foreign and can trigger an immune response. Unlike traditional vaccines, which often target a single antigen (such as a specific protein on a virus), multi-antigen presenting vaccines aim to introduce several different antigens to the immune system at once. In the context of oncology (cancer treatment), these vaccines are particularly promising because cancer cells often present a variety of abnormal proteins (antigens) on their surface. By targeting multiple antigens simultaneously, these vaccines can: 1. Enhance Immune Response: The immune system is more likely to recognize and attack cancer cells because it can respond to multiple targets, increasing the likelihood of eliminating the cancer. 2. Reduce Immune Escape: Cancer cells can sometimes mutate and stop expressing a single antigen, allowing them to evade detection. With multiple antigens targeted, the chances of immune escape are reduced. 3. Personalized Approach: Some multi-antigen vaccines can be tailored to the specific set of antigens present in a particular patient’s cancer, offering a more customized and effective treatment. This approach is seen as a cutting-edge strategy in cancer immunotherapy, as it helps harness the body’s own immune system to combat tumors more effectively. The production of multi-antigen presenting vaccines, especially for cancer treatment, is a complex process that involves several advanced biotechnological techniques. The steps involved are: 1. Antigen Selection • Tumor Antigen Identification: First, researchers identify specific antigens that are present on cancer cells but not on normal cells. These can include tumor-associated antigens (TAAs) or retention (new antigens resulting from mutations in cancer cells). • Personalization: In some cases, the patient's tumor is biopsied, and a detailed analysis (like DNA sequencing) is performed to identify unique antigens specific to that individual’s cancer. 2. Antigen Synthesis or Extraction • Synthetic Peptides: Once the antigens are identified, they can be chemically synthesized as peptides (short chains of amino acids). This is common for vaccines targeting multiple peptide antigens. • Recombinant Protein Production: If the antigen is a larger protein, it can be produced through recombinant DNA technology. This involves inserting the gene coding for the antigen into bacteria, yeast, or mammalian cells, which then produce the protein. • Viral Vectors: Some vaccines use viral vectors (like adenoviruses or lentiviruses) to deliver the genetic code for multiple antigens directly into the body’s cells. These cells then produce the antigens internally, triggering an immune response. 3. Antigen Delivery Systems To effectively deliver multiple antigens, various delivery systems are used: • Microneedle Arrays: These are patches with tiny needles that can deliver the vaccine directly to the skin, ensuring the antigens are introduced efficiently into the body’s immune system. • Nanoparticles: Antigens can be encapsulated in nanoparticles, which protect them from degradation and enhance delivery to immune cells. • Adjuvants: These are substances added to the vaccine to enhance the body’s immune response to the antigens. Examples include aluminum salts or immune-stimulating molecules. 4. Formulation • The selected antigens are combined in a way that allows for efficient presentation to the immune system. This may involve formulating them with stabilizers and preservatives to ensure the vaccine remains effective during storage and transport. 5. Preclinical Testing • Before moving to human trials, multi-antigen vaccines are tested in laboratory settings and animal models to ensure they are safe and provoke the desired immune response. 6. Clinical Trials • Once preclinical results are promising, the vaccine undergoes clinical trials in humans, starting with small groups to test for safety (Phase I), then larger groups to assess efficacy and optimal dosing (Phase II and III). 7. Large-Scale Manufacturing • If proven effective, multi-antigen vaccines are produced on a large scale. This involves scaling up the antigen production and ensuring consistent quality control through Good Manufacturing Practices (GMP). Challenges in Production: • Antigen Selection: Identifying the right combination of antigens that are unique to the cancer type or patient’s tumor. • Immune Response Optimization: Balancing the immune system’s reaction to ensure a strong, yet safe, immune response. • Production Complexity: Manufacturing multiple antigens simultaneously while ensuring they retain their structure and function. This multi-step process allows multi-antigen presenting vaccines to harness the body’s immune system for highly targeted and potent responses, particularly useful in treating cancer. Producing personalized antigens, especially in the context of cancer vaccines, offers several major benefits: 1. Targeting Unique Cancer Mutations • Precision Targeting: Each patient's cancer can have unique mutations that result in the expression of abnormal proteins (neoantigens). Personalized antigen vaccines are designed to target these specific proteins, ensuring that the immune system is directed to attack only the cancer cells, minimizing damage to healthy tissue. • Improved Efficacy: By focusing on antigens that are specific to a patient’s tumor, personalized vaccines can trigger a more effective immune response, as the vaccine is highly relevant to the cancer’s unique profile. 2. Reduced Risk of Immune Escape • Multi-Antigen Targeting: Cancer cells often evolve to evade the immune system by losing or mutating single antigens. Personalized vaccines that target multiple antigens make it harder for the cancer to escape immune detection, as it would need to simultaneously change all the targeted antigens. • Dynamic Response: Personalized vaccines can be adapted over time as the cancer evolves, allowing for a more sustained and long-term immune response. 3. Minimized Side Effects • Selective Immune Activation: Since the vaccine is designed to target only the antigens specific to the patient’s tumor, the immune system is less likely to attack normal cells, reducing the risk of off-target effects and autoimmune reactions, which are common in more generalized treatments. • Lower Toxicity: Compared to traditional treatments like chemotherapy or radiation, which affect both healthy and cancerous cells, personalized antigen vaccines tend to have fewer side effects, leading to a better quality of life for patients. 4. Enhanced Immune Memory • Long-Term Protection: Personalized vaccines can induce a strong immune memory against specific cancer antigens, which may help prevent recurrence. Once the immune system learns to recognize the antigens, it can continue to monitor and eliminate cancer cells if they reappear in the future. 5. Synergy with Other Therapies • Combination with Immunotherapy: Personalized antigen vaccines can be combined with other immunotherapies, such as immune checkpoint inhibitors, to further boost the immune system’s ability to attack cancer cells. The personalized nature of the vaccine enhances the specificity and effectiveness of these combined treatments. • Complementary to Standard Therapies: Personalized vaccines can be used alongside traditional treatments like surgery, chemotherapy, or radiation to help clean up residual cancer cells that might not be eliminated by other methods. 6. Potential for Widespread Application • Multiple Cancer Types: Personalized antigen vaccines can be tailored to a wide variety of cancers, as the approach focuses on the specific mutations within an individual’s cancer. This makes the method adaptable across different cancer types and stages, providing broader potential benefits. • Application in Early-Stage and Advanced Cancers: Personalized vaccines may be particularly useful in early-stage cancers to prevent progression and in advanced cancers to improve patient outcomes by targeting metastasized or treatment-resistant cancer cells. 7. Reduced Treatment Resistance • Overcoming Resistance Mechanisms: Some cancers develop resistance to standard treatments like chemotherapy or targeted therapies. Personalized antigen vaccines bypass these resistance mechanisms by enlisting the immune system, which can adapt to the cancer’s mutations, providing an effective strategy when other treatments fail. 8. Tailored to the Immune Environment • Optimized for Individual Patients: Personalized vaccines take into account not only the cancer's unique antigens but also the patient's immune profile. This allows the vaccine to be fine-tuned for each person’s immune system, leading to a more efficient and targeted response. In summary, the major benefits of producing personalized antigens in cancer vaccines are their ability to offer a more precise, tailored, and effective treatment with fewer side effects, while also reducing the risk of immune escape and treatment resistance. This personalized approach is seen as a key step forward in cancer immunotherapy and precision medicine. Producing personalized antigens for a multi-antigen presenting vaccine is a sophisticated process involving several biotechnological methods. Below is a comprehensive list of methods used in the preparation of personalized antigens: 1. Tumor Biopsy and Sequencing • Tumor Biopsy: A sample of the patient’s tumor tissue is collected through a biopsy, providing the material needed to identify tumor-specific antigens. • Whole Exome Sequencing (WES): This sequencing method focuses on identifying mutations in the coding regions of the patient’s tumor DNA. It allows for the detection of neoantigens, which are specific to the tumor. • RNA Sequencing (RNA-seq): RNA-seq helps measure gene expression levels in the tumor and can identify aberrantly expressed genes that could serve as antigens. • Single-Cell Sequencing: This advanced method enables researchers to analyze the genetic makeup and expression profiles of individual cells within the tumor, providing detailed information about heterogeneity and specific antigen targets. 2. Neoantigen Prediction and Selection • Bioinformatic Tools: Computational algorithms are used to analyze the sequencing data and predict which mutations will produce neoantigens that can be recognized by the patient’s immune system. Common tools include NetMHC and MuPeXI. • HLA Typing: The patient’s human leukocyte antigen (HLA) type is identified to ensure that selected antigens will bind to the specific HLA molecules, which is critical for T-cell recognition and immune activation. • Prioritization: Not all identified antigens will provoke a strong immune response. Machine learning models and immunogenicity prediction algorithms prioritize antigens that are likely to elicit robust immune reactions. 3. Antigen Synthesis • Synthetic Peptides: Short peptide sequences corresponding to the selected antigens are chemically synthesized. These peptides represent the personalized neoantigens that will be introduced to the immune system. • Recombinant Proteins: For larger or more complex antigens, recombinant DNA technology is used. The gene coding for the antigen is inserted into a host cell (such as bacteria, yeast, or mammalian cells), which then produces the antigen as a protein. • In Vitro Transcription and Translation: mRNA encoding the neoantigens can be synthesized and introduced into cells, where it is translated into proteins or peptides. This method is commonly used in mRNA vaccines. 4. Personalized Vaccine Platforms • DNA-based Vaccines: Neoantigen-encoding DNA sequences are introduced into a viral or plasmid vector, which, once inside the body, instructs cells to produce the antigens. This helps generate a strong immune response. • mRNA-based Vaccines: These vaccines use synthetic mRNA to instruct cells in the body to produce neoantigens. The mRNA is often encapsulated in lipid nanoparticles to ensure stability and efficient delivery to cells. • Peptide-based Vaccines: Personalized peptides are directly formulated into the vaccine, often alongside adjuvants to boost the immune response. These vaccines directly introduce short chains of neoantigen peptides into the body for presentation to immune cells. • Dendritic Cell Vaccines: Dendritic cells (DCs) are harvested from the patient’s blood, cultured in the lab, and “loaded” with the patient’s personalized neoantigens (peptides or proteins). These DCs are then reintroduced into the patient to stimulate T-cell activation. 5. Antigen Delivery Methods • Microneedle Arrays: These are small patches with tiny needles that can painlessly deliver antigens into the skin, which contains high concentrations of immune cells. This ensures direct and efficient antigen presentation. • Nanoparticles: Antigens or mRNA encoding antigens can be encapsulated in nanoparticles, which protect them from degradation and enhance delivery to immune cells. • Viral Vectors: Genetically engineered viruses (e.g., adenovirus, lentivirus) are used to deliver DNA or RNA coding for the personalized antigens. Once inside the cells, the virus instructs them to produce the neoantigens. • Liposomes: Lipid-based vesicles that encapsulate antigens or mRNA to improve delivery and uptake by immune cells. • Adjuvants: Compounds like Toll-like receptor agonists, cytokines (e.g., IL-2, GM-CSF), or aluminum salts are added to enhance the immune response by activating immune cells. 6. In Vitro Antigen Validation • ELISpot Assays: Enzyme-linked immunosorbent spot assays are used to test whether the patient's T-cells respond to the synthesized antigens, providing an indication of immunogenicity. • T-Cell Activation Assays: T-cells from the patient’s blood are exposed to the synthesized antigens in vitro to confirm that they are capable of recognizing and responding to the neoantigens. • MHC Binding Assays: These assays test whether the personalized antigens can bind to the patient’s MHC (major histocompatibility complex) molecules, which is a critical step in T-cell activation. 7. Formulation and Final Vaccine Production • Combining Antigens: The selected antigens (in the form of peptides, proteins, DNA, or mRNA) are combined into a single vaccine formulation, sometimes incorporating multiple types of delivery platforms for optimal results. • Stabilizers and Preservatives: Additives like buffers, salts, and stabilizers are included to ensure the antigens remain stable and active throughout storage and delivery. • Quality Control: Rigorous quality control measures are undertaken to ensure the purity, potency, and sterility of the personalized antigen vaccine before clinical use. 8. Clinical Development and Manufacturing • Good Manufacturing Practice (GMP): All steps in the production of personalized antigen vaccines must adhere to strict GMP standards to ensure consistency, safety, and efficacy. • Scale-Up for Clinical Trials: Once personalized vaccines show promise in preclinical studies, the process is scaled up to produce enough doses for clinical trials while maintaining personalized, patient-specific characteristics. These methods collectively allow for the creation of highly personalized, multi-antigen vaccines tailored to each patient’s unique tumor profile. This personalization enhances the precision and effectiveness of cancer immunotherapy, making it one of the most promising advancements in modem oncology. Possible methods for creating multi-antigen presenting vaccines are listed below, focusing specifically on the preparation and presentation of antigens: 1. CRISPR-Based Antigen Engineering • CRISPR-Cas9 gene editing can be used to precisely modify tumor cells or immune cells to express multiple antigens. By introducing mutations that encode several neoantigens, these engineered cells can serve as a source of antigen production for the vaccine. 2. Multi-Epitope Peptide Synthesis • Chemical synthesis of multi-epitope peptides allows for the combination of multiple antigenic peptide sequences into a single, long peptide. These peptides can then be processed by antigen-presenting cells (APCs), resulting in the presentation of multiple antigens simultaneously. 3. Neoantigen Libraries Using Phage Display • Phage display technology can be used to create a library of patient-specific neoantigens. This involves expressing a wide range of potential antigens on the surface of bacteriophages, which can be screened to identify those that elicit strong immune responses. 4. Exosome-Encapsulated Antigens • Exosomes, which are small vesicles naturally secreted by cells, can be loaded with multiple antigens. Exosomes can then be used to deliver these antigens directly to antigen-presenting cells, enhancing immune recognition of tumor-specific proteins. 5. Personalized Tumor Lysate Antigens • Tumor lysates can be prepared from a patient’s own tumor cells, and these lysates will contain a broad array of antigens, including mutated and overexpressed proteins. The tumor lysate is then used to pulse dendritic cells or as a direct antigen source in the vaccine. 6. Synthetic Long Peptides (SLP) Encoding Multiple Antigens • Synthetic long peptides (SLPs) can be designed to encode multiple antigenic regions within a single peptide. These peptides are processed by dendritic cells and presented via both MHC class I and class II pathways, improving the breadth of the immune response. 7. DNA Shuffling for Neoantigen Diversity • DNA shuffling involves the recombination of genetic sequences from different neoantigens to create novel, hybrid antigen sequences. This technique can produce highly diverse antigens, enhancing the immune system's ability to recognize multiple aspects of the tumor. 8. mRNA Encoding Multi-Antigen Sequences • Custom mRNA sequences can be designed to encode multiple antigens in a single transcript. Once delivered to cells, these mRNAs instruct the cells to produce several antigens, ensuring that a variety of neoantigens are presented to the immune system simultaneously. 9. Epitope-Loaded Nanoparticles • Nanoparticles can be coated with or loaded with multiple tumor-associated epitopes. These nanoparticles serve as vehicles to carry antigens into antigen-presenting cells and can even be engineered to release different antigens over time for sustained immune activation. 10. Chimeric Antigen Design • Chimeric antigens are created by fusing sequences from multiple tumor antigens into a single protein. This novel protein can be expressed in recombinant systems or produced synthetically, and it presents multiple antigenic determinants for immune system recognition. 11. Artificial Antigen-Presenting Cells (aAPCs) • Artificial antigen-presenting cells (aAPCs) can be engineered to display multiple tumor antigens on their surface. These synthetic cells are designed to mimic natural APCs and can present multiple tumor neoantigens to T-cells, enhancing the activation of a polyclonal immune response. 12. Fusion Protein Antigens • Fusion proteins are created by combining domains from several tumor antigens into a single protein. These fusion proteins can be expressed in various expression systems (such as bacteria or yeast) and serve as a rich source of multi-antigen presentation, stimulating a broad immune response. Each of these methods focuses on maximizing the immune system’s exposure to multiple tumor-specific antigens, enhancing the effectiveness of a multi-antigen presenting vaccine in targeting diverse tumor characteristics. Producing antigens from a fragment of tumor tissue involves carefully processing the tissue to isolate and prepare tumor-specific proteins while retaining their integrity and ensuring they can act as antigens without causing damage to normal tissues. This process is often referred to as the preparation of tumor lysates or autologous tumor-derived antigens. The following methods are suggested ways as ways that this can be done: 1. Tumor Biopsy and Tissue Collection • A sample of the patient's tumor is collected through a biopsy or surgery. The goal is to obtain viable tumor cells containing proteins (both mutated and normal) that can potentially act as antigens. • It is crucial to collect enough tissue for antigen extraction while maintaining the viability of the proteins for further processing. 2. Tissue Disruption and Cell Lysis • The tumor tissue is carefully disrupted to break down the cells while maintaining the integrity of the proteins. This can be done using: o Mechanical Methods: The tissue is minced, homogenized, or sonicated to release intracellular proteins without denaturing them. o Chemical Methods: Mild detergents can be used to lyse the cells and release the proteins while preserving their structure. • The resulting lysate contains a mix of tumor proteins, including both normal and abnormal (mutated) proteins, which are potential antigens. 3. Antigenic Protein Isolation and Enrichment • Once the cells are lysed, proteins need to be isolated. There are several methods to purify and enrich the tumor-specific antigens: o Centrifugation: The lysate is centrifuged to separate cell debris from soluble proteins. o Size-Exclusion Chromatography: This technique can be used to isolate proteins of specific sizes, enriching the fraction that contains intact, immunogenic proteins. o Affinity Purification: Antibodies or other binding agents can be used to selectively capture and enrich tumor-specific antigens, like mutated proteins or overexpressed proteins specific to the cancer. o Proteomics Approaches: Advanced mass spectrometry-based proteomics can identify tumor-specific proteins and mutations, allowing researchers to focus on proteins that are most likely to act as antigens. 4. Denaturation Prevention • To ensure that the tumor proteins retain their native structure and function as effective antigens, the processing must avoid excessive heat, strong chemicals, or other harsh conditions that could denature the proteins. Special buffers and controlled environments (e.g., low temperatures) are used during extraction and isolation to maintain protein structure. 5. Maintaining Antigenicity Without Causing Harm • Non-Damaging Proteins: While processing the tumor lysate, care is taken to preserve proteins that are only immunogenic in the context of the tumor environment. These include mutated proteins (neoantigens) or overexpressed tumor-associated antigens (TAAs), which are recognized by the immune system as "foreign" but do not cause damage to normal cells. • Inactivation of Live Tumor Cells: Any live tumor cells present in the lysate are inactivated (e.g., by heat or irradiation) to ensure that the lysate doesn’t contain viable, potentially harmful cancer cells, while still retaining immunogenic proteins that can function as antigens. 6. Formulation as an Antigen Source • After the tumor proteins are extracted and enriched, the lysate is prepared for presentation to the immune system. This preparation can involve: o Dendritic Cell Pulsing: The tumor lysate is loaded onto the patient’s own dendritic cells (DCs) in vitro. These DCs, which are key antigen-presenting cells, process the tumor proteins and present them to T-cells, initiating a targeted immune response. o Direct Vaccine Use: The tumor lysate can be used as a whole-cell vaccine, mixed with adjuvants that help boost the immune response. When injected into the patient, the lysate is taken up by antigen-presenting cells (APCs), which process and display the antigens on their surface to T-cells. 7. Ensuring Broad Antigen Presentation • Multivalent Antigenic Composition: The tumor lysate contains a wide range of proteins, including tumor-specific neoantigens, which reflect the genetic mutations unique to the patient’s cancer. This multivalent nature ensures that the immune system is exposed to several potential targets, increasing the likelihood of an effective immune response. • Processing for MHC Presentation: The proteins in the lysate are processed by the patient’s immune cells and presented on major histocompatibility complex (MHC) molecules to T-cells, which are then activated to recognize and attack cancer cells expressing the same antigens. 8. Quality Control • Immunogenicity Testing: Before administering the vaccine to the patient, tests such as ELISpot or T-cell activation assays may be conducted to ensure the extracted antigens can stimulate a robust immune response. • Sterility and Safety: The final product must be sterile and free of any contaminants or viable tumor cells to ensure it is safe for clinical use. By carefully processing a tumor tissue sample to extract and purify proteins, retaining their structure while inactivating harmful elements, tumor-specific antigens can be prepared for use in a vaccine. These antigens stimulate the immune system to target and destroy cancer cells without affecting healthy cells, making this a personalized and highly specific immunotherapy approach. Creating autologous tumor-derived antigens in situ (inside the body) involves methods that stimulate the patient's immune system to recognize and present tumor antigens directly from the tumor environment, without needing to extract and process the tumor tissue externally. These methods leverage the body’s own processes to generate, process, and present tumor-specific antigens to the immune system, activating an immune response directly against the tumor. Below are key methods for achieving this: 1. Oncolytic Virus Therapy • Mechanism: Oncolytic viruses are engineered to selectively infect and replicate within tumor cells, causing them to lyse (break apart). As the tumor cells are destroyed, their internal contents, including tumor-specific antigens, are released into the surrounding tissue. • In Situ Antigen Presentation: The destruction of tumor cells releases neoantigens, which are taken up by antigen-presenting cells (APCs) like dendritic cells in the tumor microenvironment. These APCs then process and present the tumor antigens to T-cells, triggering an immune response. • Examples: Viruses such as herpes simplex virus (HSV) and adenovirus are modified to selectively target tumors while boosting immune activation. 2. Thermal Ablation (Radiofrequency or Laser Ablation) • Mechanism: Thermal ablation uses heat to kill tumor cells in situ, either by applying radiofrequency waves, lasers, or microwaves. This method destroys cancer cells by increasing their temperature, causing necrosis (cell death). • In Situ Antigen Presentation: As tumor cells die, they release their contents, including tumor antigens, into the surrounding tissue. APCs can then take up these antigens, process them, and present them on MHC molecules to activate T-cells. • Immune Stimulation: The heat-induced necrosis also leads to the release of damage-associated molecular patterns (DAMPs), which stimulate the immune system and enhance antigen presentation. 3. Photodynamic Therapy (PDT) • Mechanism: PDT involves administering a photosensitizing agent to the patient, which selectively accumulates in tumor cells. When exposed to a specific wavelength of light, the agent becomes activated, generating reactive oxygen species (ROS) that kill tumor cells. • In Situ Antigen Presentation: As the tumor cells die, their antigens are released into the local environment. These antigens are then captured by APCs, which present them to T-cells, initiating an immune response. • Enhancing Immunogenicity: PDT can also induce immunogenic cell death (ICD), a type of cell death that enhances the immune system’s ability to recognize and respond to tumor antigens. 4. Cryoablation (Freezing Tumor Cells) • Mechanism: Cryoablation involves freezing tumor cells using liquid nitrogen or argon gas. This extreme cold causes ice crystals to form within the cells, leading to cell rupture and death. • In Situ Antigen Presentation: The dying tumor cells release their antigens into the local environment, which are then taken up by APCs for presentation to T-cells. • Boosting Immune Response: Cryoablation is known to induce an inflammatory response that helps recruit immune cells to the site of the tumor, enhancing the uptake and presentation of antigens. 5. Radiotherapy-Induced Antigen Release • Mechanism: Radiotherapy uses ionizing radiation to damage the DNA of tumor cells, causing cell death. It can be delivered in a targeted manner to focus on the tumor while minimizing damage to surrounding healthy tissues. • In Situ Antigen Presentation: The radiation-induced death of tumor cells releases a variety of antigens, including neoantigens, into the tumor microenvironment. APCs can then capture these antigens, process them, and present them to T-cells. • Abscopal Effect: In some cases, radiotherapy has been observed to not only kill tumor cells locally but also stimulate an immune response that targets tumors elsewhere in the body, known as the abscopal effect. 6. Immune Checkpoint Blockade with Tumor Antigen Release • Mechanism: Immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) block proteins that prevent T-cells from attacking tumor cells. These inhibitors unleash the immune system, enabling T-cells to recognize and kill tumor cells more effectively. • In Situ Antigen Presentation: As tumor cells are killed by activated T-cells, their antigens are released into the tumor microenvironment. APCs capture these antigens and present them to other immune cells, amplifying the immune response. • Combination Approaches: Immune checkpoint inhibitors can be combined with other methods (e.g., radiotherapy, oncolytic viruses) to enhance the release and presentation of tumor antigens in situ. 7. Local Injection of Immunostimulatory Agents • Mechanism: Immunostimulatory agents (such as Toll-like receptor agonists, cytokines, or CpG oligonucleotides) can be injected directly into the tumor to boost the local immune response. • In Situ Antigen Presentation: These agents stimulate APCs in the tumor microenvironment to take up and process tumor antigens more efficiently, presenting them to T-cells and enhancing the immune response. • Examples: Agents such as GM-CSF (granulocyte-macrophage colony-stimulating factor) can be used to recruit and activate APCs at the tumor site. 8. Therapeutic Vaccination with In Situ Antigen Capture • Mechanism: Vaccines containing adjuvants or immune modulators can be injected into or near the tumor. These vaccines do not contain pre-made antigens but instead stimulate the immune system to recognize and process antigens directly from the tumor. • In Situ Antigen Presentation: The immune-modulating components in the vaccine stimulate APCs to take up antigens released by the tumor and present them to T-cells, initiating an immune response against tumor-specific antigens. • Examples: Adjuvants like Poly I (a TLR3 agonist) or alum can be used to promote local antigen uptake and presentation. 9. Electroporation for Enhanced Antigen Release • Mechanism: Electroporation involves applying short electrical pulses to tumor cells, temporarily creating pores in their membranes. This allows for the release of intracellular contents, including tumor-specific antigens. • In Situ Antigen Presentation: The release of antigens from tumor cells stimulates APCs in the surrounding tissue to take up the antigens and present them to T-cells, enhancing the immune response. 10. Tumor-Autovaccination via Chemotherapy • Mechanism: Certain chemotherapeutic agents (e.g., anthracyclines, oxaliplatin) can induce immunogenic cell death (ICD), a form of cell death that promotes the release of tumor antigens in a way that stimulates the immune system. • In Situ Antigen Presentation: The dying tumor cells release antigens into the microenvironment, which are captured by APCs for presentation to T-cells. The immune system is then activated to recognize and attack remaining tumor cells based on these antigens. 11. Microwave Ablation • Mechanism: Microwave ablation uses high-frequency microwaves to generate heat, which induces cell death within the tumor. This method is often used to treat solid tumors like liver or lung cancers. • In Situ Antigen Presentation: Similar to other ablation methods, the heat-induced cell death releases tumor antigens into the local environment, which APCs take up and present to the immune system, enhancing T-cell activation. 12. Nanoparticle-Based Antigen Release Modulation • Mechanism: Nanoparticles loaded with immune-modulating agents or antigens can be injected into the tumor, where they either stimulate tumor cell death or enhance antigen presentation by local APCs. • In Situ Antigen Presentation: These nanoparticles can help release tumor antigens in a controlled manner, stimulating local dendritic cells to take up and present the antigens to T-cells. By utilizing these in situ methods, autologous tumor-derived antigens are released within the patient’s body, effectively allowing the immune system to recognize and respond to tumor-specific antigens naturally and efficiently. These approaches minimize the need for external processing while harnessing the body’s innate mechanisms to initiate a personalized immune response against the tumor. Implantable devices or systems designed to elicit the production of tumor-specific antigens aim to enhance the immune response against tumors by generating or presenting antigens directly within the body. Examples of devices and systems that could be used for this purpose are: 1. Implantable Bioreactors • Description: These are small devices that can be implanted into the body to cultivate tumor cells or cells engineered to produce tumor-specific antigens. • Function: The bioreactor provides a controlled environment for the growth and secretion of tumor antigens. Tumor cells or engineered cells within the bioreactor release antigens into the surrounding tissue, where they can be captured by antigen-presenting cells. • Design: The device would be designed to ensure sustained antigen release and prevent immune tolerance or overreaction. 2. Antigen-Delivery Microchips • Description: Microchips can be implanted and programmed to release specific antigens or antigen-coding materials in a controlled manner. • Function: These chips could contain synthetic antigens or DNA / mRNA encoding tumorspecific antigens. The microchip releases these materials gradually, stimulating local immune cells and generating an immune response against the tumor. • Design: The chip would be designed to release antigens at a controlled rate, potentially using microelectromechanical systems (MEMS) technology. 3. Bioengineered Tumor-Cell Implants • Description: Implants containing bioengineered tumor cells or cells genetically modified to produce tumor-specific antigens. • Function: These cells could be engineered to produce and release tumor antigens or even express tumor antigens on their surface. When implanted, they continuously produce these antigens, which are taken up by local immune cells. • Design: The implant would need to be designed to avoid immune rejection and to ensure sustained antigen production. 4. Gene Therapy Implants • Description: Implants containing viral vectors or other gene delivery systems that introduce genes encoding tumor-specific antigens into local tissues. • Function: The gene therapy approach involves delivering DNA or RNA coding for tumor antigens directly into the body. The implanted device could be a reservoir or scaffold that slowly releases these gene vectors. • Design: The device would be designed to protect the vectors and facilitate their uptake by local cells. 5. Dendritic Cell Implants • Description: Implants containing autologous or engineered dendritic cells that have been pre-loaded with tumor antigens. • Function: These dendritic cells are implanted into the body where they present tumor antigens to T-cells, thereby stimulating an immune response. • Design: The implant would be designed to support the viability of the dendritic cells and ensure they remain functional for a sufficient period. 6. Stimulating Antigen-Delivery Meshes • Description: Biodegradable meshes or scaffolds implanted into or near the tumor site that can release tumor-specific antigens or antigen-coding materials. • Function: The mesh gradually releases antigens over time, allowing for sustained antigen presentation and immune stimulation. • Design: The material and structure of the mesh would be designed to provide controlled release and maintain antigen stability. 7. Implantable Electroporation Devices • Description: Devices that use electrical pulses to introduce antigen-coding DNA or mRNA into tumor cells or surrounding tissue. • Function: Electroporation can transiently open cell membranes, allowing for the uptake of antigen-coding materials and subsequent production of tumor-specific antigens. • Design: The device would include electrodes and be designed for precise delivery of electrical pulses to maximize antigen uptake and minimize damage. 8. Immunostimulatory Implantable Biomaterials • Description: Biomaterials implanted at or near the tumor site that can deliver immunostimulatory agents or adjuvants to enhance local antigen presentation. • Function: These materials can be designed to deliver substances that boost the immune response to antigens already present in the tumor or to antigens delivered by the device itself. • Design: The biomaterials would be engineered to release agents in a controlled manner and support an enhanced immune response. 9. Hydrogel-Based Antigen Release Systems • Description: Hydrogels implanted into the body that can encapsulate and gradually release tumor-specific antigens or antigen-coding materials. • Function: The hydrogel provides a matrix for sustained release of antigens, which are then taken up by local immune cells. • Design: The hydrogel would be designed for biocompatibility and controlled release kinetics. 10. Nanoparticle-Based Implants • Description: Nanoparticles incorporated into an implant that can release or deliver tumor-specific antigens or antigen-coding materials. • Function: Nanoparticles can be engineered to target specific tumor sites and release antigens or genetic material, facilitating local antigen presentation and immune response. • Design: The implant would need to ensure that nanoparticles are stable and effectively release their contents over time. 11. Biohybrid Implants • Description: Hybrid devices combining biological components (e.g., live cells) with synthetic materials to create a platform for antigen production and delivery. • Function: These implants can be designed to produce and release tumor-specific antigens through biological processes, while the synthetic components support stability and functionality. • Design: The biohybrid implant would need to balance biological activity with material stability and immune compatibility. 12. Immunoengineering Scaffolds • Description: Scaffolds implanted into the body that provide a structured environment for the growth and activation of immune cells capable of processing and presenting tumor antigens. • Function: These scaffolds can be designed to support the in situ growth and activation of APCs or other immune cells, which then process tumor antigens present in the local environment. • Design: The scaffold would be designed to support cellular growth, antigen presentation, and immune cell activation. The devices outlined for implantable devices or systems to elicit the production of tumor-specific antigens are largely novel and represent cutting-edge approaches in cancer immunotherapy. However, some technologies have already seen practical implementation or are in advanced stages of research and development i.e: 1. Implantable Bioreactors • Novelty: While bioreactors are common in laboratory settings for cell culture, implantable versions designed for continuous antigen production in the body are still largely in the research phase. • Examples: No widely adopted implantable bioreactor specifically for tumor antigen production exists yet. 2. Antigen-Delivery Microchips • Novelty: Microchips for antigen delivery are an emerging technology. Some microchipbased drug delivery systems have been developed, but specific microchips for controlled antigen release in cancer therapy are still in experimental stages. • Examples: Limited clinical examples; primarily under research. 3. Bioengineered Tumor-Cell Implants • Novelty: The concept of implanting bioengineered cells for antigen production is relatively new. Some research involves implantable cell systems for therapy, but commercial products are not widely available. • Examples: Research studies have explored similar approaches, but practical, widespread applications are still developing. 4. Gene Therapy Implants • Novelty: Gene therapy approaches using implants to deliver antigen-coding genes are innovative. While gene therapy is a well-established field, specific implants for in situ antigen production are still emerging. • Examples: Gene therapy using vectors has been implemented, but localized, implantable devices for antigen production are still under development. 5. Dendritic Cell Implants • Novelty: Implantable dendritic cell systems are an area of ongoing research. While dendritic cell vaccines have been used in clinical settings, implantable versions are less common. • Examples: Dendritic cell vaccines exist (e.g., Provenge for prostate cancer), but implantable versions are experimental. 6. Stimulating Antigen-Delivery Meshes • Novelty: The use of biodegradable meshes for controlled antigen delivery is a newer concept. Research is ongoing, but practical applications are still in development. • Examples: No commercial products yet; mainly research-focused. 7. Implantable Electroporation Devices • Novelty: Electroporation for gene delivery is well-established in research, but implantable devices specifically for in situ antigen production are still novel. • Examples: Electroporation devices are used in some experimental settings, but implantable versions are still emerging. 8. Immunostimulatory Implantable Biomaterials • Novelty: The use of biomaterials to deliver immunostimulatory agents is an innovative approach. While similar biomaterial systems are being developed, specific implantable devices are relatively new. • Examples: Research in biomaterials for drug delivery and immunotherapy is active, but specific implantable devices for cancer antigen production are still under development. 9. Hydrogel-Based Antigen Release Systems • Novelty: Hydrogels for controlled antigen release are a promising area. Research on hydrogel systems for drug and antigen delivery is ongoing, but implantable versions are still emerging. • Examples: Hydrogel-based systems are used in drug delivery research, but specific applications for tumor antigens are still in development. 10. Nanoparticle-Based Implants • Novelty: Nanoparticles for targeted drug delivery and antigen delivery are an active area of research. While nanoparticles are used in various therapeutic contexts, implantable devices for controlled antigen release are still novel. • Examples: Nanoparticle systems are being developed for drug delivery, but specific implantable systems for cancer antigens are still experimental. 11. Biohybrid Implants • Novelty: The concept of biohybrid implants combining biological components with synthetic materials is innovative. Research is ongoing, but practical, widely adopted systems are still in development. • Examples: Some experimental biohybrid systems exist, but practical applications for cancer antigen production are still emerging. 12. Immunoengineering Scaffolds • Novelty: Immunoengineering scaffolds designed for antigen production and immune cell activation are an emerging field. While scaffolds fortissue engineering are common, those specifically for in situ antigen production are relatively new. • Examples: Research is active, but commercial products are still in development. While some technologies and concepts mentioned are being actively researched and developed, many are still in the experimental phase and have not yet been widely adopted in clinical practice. The field of implantable devices for producing tumor-specific antigens represents an exciting frontier with the potential to revolutionize cancer immunotherapy. Examples are: 1. Implantable Bioreactors Description: An implantable bioreactor is a small, biocompatible device designed to cultivate tumor cells or engineered cells that produce tumor-specific antigens directly within the body. The device features a controlled environment for cell growth and antigen secretion. Novelty: • Design of the Bioreactor: Incorporates advanced materials and structures to create a controlled environment for antigen production. • Antigen Production in Vivo: The ability to continuously produce and release tumorspecific antigens inside the body. • Biocompatibility and Longevity: Engineered to ensure long-term operation without rejection or degradation. Inventive Steps: • Material Composition: Use of novel biocompatible materials that support cell viability and antigen production. • Controlled Environment: Development of an internal environment that mimics natural conditions for optimal antigen secretion. • Antigen Release Mechanism: Incorporation of a controlled release system for gradual antigen delivery. 2. Antigen-Delivery Microchips Description: Microchips implanted in the body that release specific antigens or antigen-coding materials in a controlled manner. These chips use microelectromechanical systems (MEMS) technology. Novelty: • Microchip Technology: Integration of MEMS for precise control of antigen release. • Customizable Antigen Release: Ability to program the chip to release different antigens or quantities over time. Inventive Steps: • Chip Design: Development of microchips with microfluidic channels or reservoirs for controlled release. • Programming Interface: Technology for remotely or pre-programmed control of antigen release. • Biocompatibility: Design of the chip to prevent adverse reactions in the body. 3. Bioengineered Tumor-Cell Implants Description: Implants containing bioengineered tumor cells or cells engineered to produce tumor-specific antigens. These cells are inserted into the body to secrete antigens directly. Novelty: • Bioengineering of Cells: Genetic modification of cells to produce tumor-specific antigens within the body. • Implantable Systems: Creation of a device that supports and maintains the bioengineered cells. Inventive Steps: • Cell Engineering: Techniques for stable and efficient expression of antigens in the engineered cells. • Implant Design: Structure and materials that support cell viability and function. • Antigen Delivery: Methods for ensuring effective release and presentation of antigens to the immune system. 4. Gene Therapy Implants Description: Implants that deliver viral vectors or other gene delivery systems encoding tumor-specific antigens into local tissues. Novelty: • Implantable Gene Delivery Systems: Development of devices for localized and sustained gene delivery. • Targeted Antigen Production: Use of specific vectors to ensure localized production of antigens. Inventive Steps: • Vector Design: Innovation in vector types and delivery mechanisms to enhance gene transfer. • Implant Design: Development of an implantable system that protects vectors and facilitates their release. • Local Expression Control: Methods to control and monitor gene expression and antigen production. 5. Dendritic Cell Implants Description: Implants containing dendritic cells that have been pre-loaded with tumor antigens. The cells are implanted to present antigens to T-cells. Novelty: • Implantable Dendritic Cell Systems: Development of a device for maintaining and functioning of dendritic cells in vivo. • Pre-loaded Antigens: Method for loading and preserving antigens on dendritic cells within the implant. Inventive Steps: • Cell Preservation: Techniques to maintain dendritic cell viability and function after implantation. • Antigen Loading: Methods for efficiently loading dendritic cells with tumor-specific antigens. • Implant Design: Structure to support cell function and integration with the body’s immune system. 6. Stimulating Antigen-Delivery Meshes Description: Biodegradable meshes implanted at or near the tumor site that gradually release tumor-specific antigens. Novelty: • Biodegradable Materials: Use of novel materials that degrade at controlled rates to release antigens. • Localized Antigen Delivery: Continuous and localized release of antigens in the tumor microenvironment. Inventive Steps: • Material Composition: Development of materials with controlled degradation and antigen release properties. • Mesh Design: Engineering the mesh to ensure uniform antigen distribution and release. • Biocompatibility: Ensuring the mesh is compatible with surrounding tissues and minimizes immune reactions. 7. Implantable Electroporation Devices Description: Devices that apply electrical pulses to transiently open cell membranes, allowing for the introduction of antigen-coding DNA or mRNA into tumor cells. Novelty: • Implantable Electroporation: Development of a device that can precisely deliver electrical pulses in a controlled manner. • Localized Gene Delivery: Use of electroporation for targeted delivery of genetic material encoding tumor-specific antigens. Inventive Steps: • Electroporation Technology: Design of electrodes and pulsing protocols for optimal gene transfer. • Implant Design: Incorporation of the electroporation system into an implantable device. • Antigen Expression Control: Techniques to regulate and monitor gene expression within targeted cells. 8. Immunostimulatory Implantable Biomaterials Description: Biomaterials implanted at the tumor site that deliver immunostimulatory agents or adjuvants to enhance local antigen presentation. Novelty: • Biomaterial Design: Use of advanced materials that can deliver immunostimulatory agents in a controlled manner. • Localized Immune Activation: Targeted delivery of agents to enhance immune response against tumor antigens. Inventive Steps: • Agent Delivery: Engineering materials to control the release of immunostimulatory agents. • Biocompatibility and Efficacy: Ensuring the biomaterials support local immune activation without causing adverse effects. • Design Features: Development of implantable systems that integrate with the tumor microenvironment. 9. Hydrogel-Based Antigen Release Systems Description: Hydrogels implanted into the body that encapsulate and gradually release tumor-specific antigens or antigen-coding materials. Novelty: • Hydrogel Technology: Use of novel hydrogels for controlled antigen release and protection of sensitive materials. • Gradual Release: Engineering hydrogels to release antigens over an extended period. Inventive Steps: • Hydrogel Formulation: Development of hydrogels with specific release kinetics and antigen compatibility. • Implant Design: Structure and stability of the hydrogel to ensure effective and sustained release. • Biocompatibility: Ensuring the hydrogel does not induce adverse reactions in the body. 10. Nanoparticle-Based Implants Description: Implants incorporating nanoparticles that can deliver tumor-specific antigens or antigen-coding materials directly to the tumor site. Novelty: • Nanoparticle Integration: Use of nanoparticles for targeted delivery of antigens within an implantable device. • Controlled Release: Engineering of nanoparticles to release antigens in a controlled manner. Inventive Steps: • Nanoparticle Design: Development of nanoparticles with specific targeting and release properties. • Implant System: Integration of nanoparticles into a device that supports controlled delivery. • Targeting Mechanisms: Techniques to ensure nanoparticles are directed to the tumor site effectively. 11. Biohybrid Implants Description: Devices combining biological components (e.g., live cells) with synthetic materials to produce and deliver tumor-specific antigens. Novelty: • Biohybrid Concept: Integration of living cells with synthetic materials for enhanced antigen production and delivery. • Sustained Functionality: Design to ensure long-term operation and antigen production. Inventive Steps: • Biohybrid Design: Combination of biological and synthetic components in a functional implant. • Cell Function Support: Methods to maintain cell viability and activity within the device. • Antigen Delivery: Techniques to release antigens in a controlled and effective manner. 12. Immunoengineering Scaffolds Description: Scaffolds implanted into the body that provide a structured environment for immune cells to process and present tumor-specific antigens. Novelty: • Immunoengineering Approach: Use of scaffolds to support the activation and function of immune cells in situ. • Antigen Processing: Design of scaffolds to facilitate the processing and presentation of antigens to T-cells. Inventive Steps: • Scaffold Design: Engineering scaffolds with properties that support immune cell growth and function. • Antigen Interaction: Methods to ensure effective interaction between antigens and immune cells. • Biocompatibility and Functionality: Ensuring the scaffold integrates well with the body and supports ongoing immune activation. Suitable materials, design features, and local environmental parameters for each system are given below, focusing on aspects that would contribute to their efficacy: 1. Implantable Bioreactors Aspect Details Materials Biocompatible polymers (e.g., PEG, PLA), ceramic materials, hydrogels - Controlled release mechanisms Design Features - Internal compartments for cell growth - Protective coatings - Temperature control Local Environmental - pH regulation Parameters - Nutrient supply - Waste removal mechanisms 2. Antigen-Delivery Microchips Aspect Details Materials Silicon, biocompatible polymers, MEMS components, conductive materials - Programmable release control Design Features - Microfluidic channels - Encapsulation for antigen stability - Electrical stimulation Local Environmental - Temperature regulation Parameters - Humidity control - Biological compatibility 3. Bioengineered Tumor-Cell Implants Aspect Details Materials Biocompatible scaffolds (e.g., collagen, hyaluronic acid), cell encapsulation materials Aspect Details - Cell support and viability structures Design Features - Controlled release systems - Cell protection mechanisms - Oxygenation Local Environmental - Nutrient and waste exchange Parameters - Temperature stability - pH balance 4. Gene Therapy Implants Aspect Details Materials Biodegradable polymers, viral vectors, gene delivery systems (e.g., liposomes, nanoparticles) - Controlled release of vectors Design Features - Protection of genetic material - Targeted delivery systems Local Environmental - Electrical fields for gene transfer (if applicable) Parameters - Temperature control - pH balance 5. Dendritic Cell Implants Aspect Details Materials Biocompatible hydrogels, collagen, cell culture media - Cell preservation Design Features - Antigen loading - Implant structure supporting cell function - Temperature regulation - Nutrient supply Local Environmental Parameters - Oxygenation - Removal of waste products 6. Stimulating Antigen-Delivery Meshes Materials Biodegradable polymers (e.g., PLA, PCL), hydrogels, natural polymers (e.g., alginate) - Controlled degradation rates Design Features - Uniform antigen distribution - Mesh porosity - Local pH Local Environmental - Temperature Parameters - Humidity - Enzyme activity for degradation 7. Implantable Electroporation Devices Aspect Details Materials Conductive materials (e.g., platinum, titanium), biocompatible polymers - Electrode placement Design Features - Controlled pulsing mechanism - Biocompatible insulation - Electrical field strength Local Environmental - Pulse duration and frequency Parameters - Temperature regulation 8. Immunostimulatory Implantable Biomaterials Aspect Details Materials Biocompatible polymers (e.g., poly(lactic-co-glycolic acid)), immunostimulatory agents (e.g., cytokines) - Controlled release of immunostimulatory agents Design Features - Material porosity - Integration with tissue -pH Local Environmental - Temperature Parameters - Immune cell interaction - Local cytokine levels 9. Hydrogel-Based Antigen Release Systems Materials Hydrogels (e.g., alginate, agarose), encapsulated antigens or DNA / RNA - Gel matrix composition Design Features - Controlled release properties - Antigen stability within the hydrogel - Local pH Local Environmental - Temperature Parameters - Moisture levels - Enzyme activity affecting hydrogel degradation 10. Nanoparticle-Based Implants Aspect Details Materials Nanoparticles (e.g., liposomes, polymeric nanoparticles), biocompatible polymers - Targeting mechanisms Design Features - Controlled release - Stability of nanoparticles - Temperature Local Environmental -pH Parameters - Local cellular interactions - Enzyme activity affecting nanoparticles 11. Biohybrid Implants Aspect Details Materials Biological cells, synthetic polymers, biocompatible coatings - Integration of biological and synthetic components Design Features - Support for cell function - Controlled antigen release - Cellular nutrient supply - Oxygenation Local Environmental Parameters - Temperature - pH balance 12. Immunoengineering Scaffolds Scaffolding materials (e.g., collagen, synthetic polymers), Materials immunomodulatory agents - Scaffold structure for immune cell support Design Features - Antigen presentation surfaces - Material porosity - Temperature Local Environmental - pH Parameters - Cellular infiltration - Nutrient and oxygen supply Each of these systems has distinct material requirements, design considerations, and local environmental parameters crucial for ensuring efficacy and optimizing therapeutic outcomes. The present invention encompasses novel implantable systems designed to produce and deliver tumor-specific antigens directly within the body. These systems leverage advanced materials and cutting-edge technologies to facilitate controlled antigen release and localized immune activation. The invention aims to enhance the efficacy of cancer immunotherapy by providing sustained and targeted antigen exposure, thereby improving the immune system’s ability to recognize and combat tumors. 1. Implantable Bioreactors The implantable bioreactor system comprises a small, biocompatible device engineered to cultivate and sustain tumor cells or bioengineered cells capable of producing tumor-specific antigens. The bioreactor utilizes advanced materials such as biocompatible polymers (e.g., polyethylene glycol, polylactic acid) and ceramics to create a controlled internal environment. This environment maintains optimal conditions for cell growth, including temperature, pH, and nutrient supply, while ensuring waste removal. The bioreactor’s design features compartments for cell culture and mechanisms for the gradual release of antigens, ensuring long-term antigen production without adverse effects on surrounding tissues. 2. Antigen-Delivery Microchips Antigen-delivery microchips represent a sophisticated technology that integrates microelectromechanical systems (MEMS) to achieve precise control over antigen release. These microchips are composed of silicon and biocompatible polymers and feature microfluidic channels or reservoirs that encapsulate and release tumor-specific antigens. The microchips are programmable, allowing for customizable release schedules and dosages. The system’s design includes protective coatings to ensure the stability of encapsulated antigens and a remote or preprogrammed control interface to manage release patterns. Local environmental parameters such as electrical stimulation, temperature regulation, and humidity control are meticulously managed to optimize antigen delivery. 3. Bioengineered Tumor-Cell Implants This system involves implanting bioengineered cells, which have been genetically modified to produce tumor-specific antigens, directly into the body. The implants are made from biocompatible scaffolds (e.g., collagen, hyaluronic acid) that support cell viability and function. The implants are designed to provide a controlled environment for antigen production, including oxygenation, nutrient exchange, and waste removal. The bioengineered cells are protected within the implant to ensure sustained antigen production while minimizing immune rejection. 4. Gene Therapy Implants Gene therapy implants are designed to deliver viral vectors or other gene delivery systems encoding tumor-specific antigens to local tissues. These implants utilize biodegradable polymers and advanced gene delivery technologies such as liposomes or nanoparticles. The implant system includes controlled release mechanisms for the vectors and protective features to maintain genetic material stability. Local parameters such as electrical fields for gene transfer, temperature control, and pH balance are critical for effective gene expression and antigen production. 5. Dendritic Cell Implants Dendritic cell implants involve pre-loading dendritic cells with tumor-specific antigens and implanting them to present these antigens to T-cells. The implants use biocompatible hydrogels or collagen to preserve dendritic cell function and facilitate antigen presentation. The system supports nutrient supply, temperature regulation, and waste removal to maintain cell viability. The dendritic cells are engineered to enhance immune activation against tumor antigens, improving therapeutic outcomes. 6. Stimulating Antigen-Delivery Meshes These biodegradable meshes are designed to deliver tumor-specific antigens overtime. Composed of materials such as polylactic acid, polycaprolactone, or natural polymers like alginate, the meshes gradually release antigens through controlled degradation. The mesh structure ensures uniform antigen distribution and effective local delivery. Environmental parameters such as local pH, temperature, and enzyme activity influence degradation rates and antigen release, optimizing therapeutic efficacy. 7. Implantable Electroporation Devices Electroporation devices apply controlled electrical pulses to transiently open cell membranes, facilitating the introduction of antigen-coding DNA or mRNA into tumor cells. These devices incorporate conductive materials such as platinum or titanium and biocompatible polymers. The design features precise electrode placement and pulsing mechanisms to optimize gene transfer. Parameters such as electrical field strength, pulse duration, and temperature regulation are crucial for effective antigen production. 8. Immunostimulatory Implantable Biomaterials This system employs biomaterials to deliver immunostimulatory agents or adjuvants directly to the tumor site. Utilizing materials like poly(lactic-co-glycolic acid) and immunostimulatory agents (e.g., cytokines), the biomaterials are designed to release agents in a controlled manner. The system features porous structures and integration capabilities to enhance local immune response. Key parameters include local pH, temperature, and immune cell interaction, all of which influence the effectiveness of the immunostimulatory treatment. 9. Hydrogel-Based Antigen Release Systems Hydrogel-based systems use hydrogels such as alginate or agarose to encapsulate and release tumor-specific antigens. The hydrogels are engineered to provide controlled release properties and protect sensitive materials. The system’s efficacy is influenced by environmental factors such as local pH, temperature, moisture levels, and enzyme activity affecting hydrogel degradation. 10. Nanoparticle-Based Implants Nanoparticle-based implants incorporate nanoparticles for targeted delivery of tumor-specific antigens. Materials include liposomes, polymeric nanoparticles, and biocompatible polymers. The implants are designed for controlled release and stability of nanoparticles. Local parameters such as temperature, pH, cellular interactions, and enzyme activity impact the effectiveness of the nanoparticle-based delivery system. 11. Biohybrid Implants Biohybrid implants combine biological cells with synthetic materials to produce and deliver tumor-specific antigens. The implants integrate live cells with synthetic polymers and biocompatible coatings to support cell function and antigen release. Local parameters such as cellular nutrient supply, oxygenation, temperature, and pH balance are essential for maintaining cell viability and optimizing antigen production. 12. Immunoengineering Scaffolds Immunoengineering scaffolds provide a structured environment for immune cells to process and present tumor-specific antigens. The scaffolds use materials like collagen and synthetic polymers, incorporating immunomodulatory agents to support immune cell function. The design features include antigen presentation surfaces and scaffold porosity. Key environmental parameters include temperature, pH, cellular infiltration, and nutrient and oxygen supply. Each of these implantable systems represents a novel approach to enhancing cancer immunotherapy by providing localized and sustained production of tumor-specific antigens. The systems utilize advanced materials, innovative design features, and controlled local environmental parameters to optimize efficacy and therapeutic outcomes. The comprehensive nature of these inventions ensures that they are not only novel but also practically implementable, offering significant potential for advancement in cancer treatment. The above description provides detailed examples of the technology useable in the invention. The invention will be described in more detail below, with reference to the schematic drawings where: Figure 1 shows an implantable bioreactor; Figure 2 shows an antigen delivery microchip; Figure 3 shows a bioengineered tumour cell implant; Figure 4 shows a gene therapy implant; and Figure 5 shows a hydrogel based antigen release system. Figure 1: Implantable Bioreactor Description: This figure shows a cross-sectional view of an implantable bioreactor designed to cultivate and sustain tumor cells or bioengineered cells for continuous antigen production. Figure 1 shows a biocompatible polymer casing 1 surrounding a cell culture compartment 4, nutrient supply compartment 2, and associated conduits 7 between the nutrient supply compartment 2 and cell culture compartment 4, and waste removal compartment 5, and associated waste removal conduits 8. Surrounding the compartments, within the outer surrounding casing 1 a chamber 3 containing pH regulating gel or buffer solution (as indicated by the striations); and conduits 6 between the cell culture compartment 4 and external environment for the release of the antigens. Annotations: 1. Biocompatible Polymer Casing: Protects the internal components and ensures compatibility with body tissues. 2. Cell Culture Compartments: Chambers within the bioreactor where tumor or bioengineered cells are housed. 3. Controlled Release Mechanism: System for gradual release of tumor-specific antigens into the surrounding tissue. 4. Nutrient Supply Inlet: Provides essential nutrients to the cultured cells. 5. Waste Removal Outlet: Facilitates the removal of metabolic waste from the cell compartments. 6. Temperature and pH Regulation System: Maintains optimal environmental conditions for cell growth. Figure 2: Antigen-Delivery Microchip Description: This figure illustrates a microchip-based system that uses microelectromechanical systems (MEMS) technology for programmable antigen delivery. Protective microchip housing 1 containing a programmable control interface 9, linked via conduits 7 with the antigen compartment 10, and nutrient reservoir 11 connected via conduits 8 with the antigen compartment 10, surrounded by a pH regulating medium 3, buffer or gel (as indicated by the striations); and conduits 6 between the antigen compartment 10 and external environment for the release of the antigens. Annotations: 1. Microchip Housing: Encases the microelectromechanical components and antigen reservoirs. 2. Microfluidic Channels: Direct pathways for antigen movement within the microchip. 3. Antigen Reservoirs: Contain tumor-specific antigens for controlled release. 4. Programmable Control Interface: Allows for customization of antigen release schedules and dosages. 5. Protective Coating: Ensures stability and prevents degradation of encapsulated antigens. 6. Electrical Contacts: Facilitate programmable control and communication with the chip. Figure 3: Bioengineered Tumor-Cell Implant Description: This figure depicts an implant containing bioengineered cells designed to produce tumor-specific antigens in situ. Protective housing 1 containing pH-controlled medium containing scaffold matrix 12, supporting the bioengineered tumour cells 13, connected via conduits 14 to a nutrient reservoir 15 and oxygen containing layer 16 connected to the scaffold matrix layer 12 via conduits 17; conduits 6 on the protective housing for gradual controlled release of the antigens produced by the bioengineered cells; where-by waste is absorbed directly into scaffold matrix 12 supporting medium. Annotations: 1. Biocompatible Scaffold: Provides structural support and stability for the implanted cells. 2. Bioengineered Tumor Cells: Genetically modified cells that produce tumor-specific antigens. 3. Controlled Release System: Mechanism for gradual antigen release into the surrounding tissue. 4. Oxygenation and Nutrient Channels: Ensure proper cell function and survival. 5. Waste Removal Pathways: Facilitate the removal of metabolic waste from the cell environment. Figure 4: Gene Therapy Implant Description: This figure shows an implantable device designed for localized delivery of gene therapy vectors encoding tumor-specific antigens. A cross-section schematic of a biodegradable casing 1, containing gene delivery vectors 18 (containing the antigen-coding genetic material) suspended in a protective (buffered-gel) medium 19, and the outer casing containing pores 6 for the release of the gene delivery vectors. Adhered to the outer casing 1 is an electrode array 20 with built-in program and power supply to provide bursts of energy to effect electroporation through local cells for enhanced vector transfer (and therefore antigen coding genetic material transfer). Annotations: 1. Biodegradable Polymer Casing: Encases the gene delivery vectors and provides structural support. 2. Gene Delivery Vectors: Carriers for tumor-specific antigen-coding genetic material. 3. Controlled Release Mechanism: Ensures sustained release of vectors into local tissues. 4. Protection Layer: Preserves the integrity of the genetic material. 5. Electrode Array (if applicable): Used for electroporation to enhance gene transfer. Figure 5: Hydrogel-Based Antigen Release System Description: This figure illustrates a hydrogel system for encapsulating and gradually releasing tumor-specific antigens. A cross-section schematic of a antigen containing moisture retentive protective layer 21, enclosing a hydrogel medium 22 dispersed with antigens 23 for release into the surrounding medium via pores 6. Annotations: 1. Hydrogel Matrix: Encapsulates the antigens and controls their release. 2. Encapsulated Antigens: Tumor-specific antigens within the hydrogel. 3. Controlled Release Zones: Areas within the hydrogel designed for gradual antigen release. 4. Degradation Pathways: Routes for the hydrogel’s degradation, influencing antigen release rates. 5. Moisture Retention Layer: Ensures the hydrogel remains hydrated and functional. The invention pertains to advanced implantable systems designed for in situ production and controlled delivery of tumor-specific antigens to enhance cancer immunotherapy. Benefits of using implantable systems to produce tumor-specific antigens directly within the body, as opposed to producing them outside of the body are given below: 1. Localized Antigen Production: Implantable systems ensure that antigens are produced directly at or near the tumor site, increasing the likelihood of effective antigen presentation to the local immune cells. 2. Continuous Antigen Supply: These systems can provide a sustained and controlled release of antigens over time, offering a continuous supply that enhances immune system activation and reduces the need for frequent treatments. 3. Reduced Antigen Degradation: Antigens produced and delivered within the body are less susceptible to degradation compared to those manufactured externally and then transported, preserving their therapeutic efficacy. 4. Enhanced Immune Response: Local production of antigens can lead to a more robust and specific immune response, as the antigens are presented in the natural tissue environment, facilitating better recognition by immune cells. 5. Minimized Side Effects: By focusing antigen production at the tumor site, implantable systems reduce the potential for systemic side effects and unintended immune responses that can occur with external production and delivery methods. 6. Targeted Delivery: Implantable systems can be designed to target specific tumor types or cells, allowing for more precise and effective immune activation without affecting healthy tissues. 7. Reduced Manufacturing Complexity: Producing antigens in situ eliminates the need for complex and costly external production processes, such as cell culture and purification, simplifying the overall treatment regimen. 8. Enhanced Patient Compliance: Continuous or intermittent delivery of antigens through implantable systems can reduce the frequency of patient visits and treatments, improving overall patient adherence and convenience. 9. Personalized Therapy: Implantable systems can be tailored to individual patients, allowing for the customization of antigen types and release rates based on the specific characteristics of the patient’s tumor. 10. Adaptability: Implantable systems can be engineered to respond to changes in the tumor microenvironment or the patient’s immune status, allowing for dynamic adjustments in antigen production and release. 11. Integration with Tumor Microenvironment: Direct production within the body allows the system to integrate with the tumor microenvironment, potentially enhancing antigen uptake by dendritic cells and improving immune activation. 12. Potential for Dual Functionality: Some implantable systems may offer dual functionality, such as simultaneous antigen production and delivery of immune modulators, further boosting the therapeutic effect. 13. Minimized Risk of Contamination: On-site production reduces the risk of contamination and complications associated with transporting and handling antigens externally, leading to safer therapeutic applications. 14. Reduced Risk of Immunogenicity: Antigens produced in situ are more likely to be recognized as self by the immune system, potentially reducing the risk of adverse immunogenic reactions compared to externally produced antigens. 15. Enhanced Integration with Existing Therapies: Implantable systems can be used in conjunction with other treatments, such as chemotherapy or radiation, to create a comprehensive and synergistic therapeutic approach. These benefits collectively contribute to the potential for improved efficacy, safety, and convenience of cancer immunotherapy using implantable antigen production systems. Novelty and Inventiveness of Implantable Antigen Production Systems 1. In Situ Antigen Production: • Novelty: The concept of producing antigens directly within the body, rather than synthesizing them externally and then delivering them, represents a significant advancement. Current methods primarily rely on external production facilities where antigens are synthesized, purified, and then administered through injections or other delivery systems. Implantable systems that produce antigens in situ offer a new approach by integrating the production and delivery processes, eliminating the need for external handling and transportation of sensitive materials. • Inventiveness: This approach is inventive because it addresses multiple challenges associated with external antigen production, such as degradation, contamination risks, and complex logistics. By creating a localized antigen production environment, the implantable system ensures that antigens are continuously available in proximity to the tumor, enhancing immune system activation and reducing systemic side effects. 2. Controlled and Sustained Release: • Novelty: The ability to control and sustain antigen release over time through implantable systems is a novel advancement. Existing methods typically involve periodic administration of antigens, which can lead to inconsistent immune responses and require frequent patient visits. Implantable systems offer a way to provide a steady and regulated supply of antigens, which is not a standard feature of current treatments. • Inventiveness: The inventive aspect lies in the precise control mechanisms integrated into these systems, allowing for customizable release schedules and dosages. This capability can be fine-tuned to match the specific needs of the patient and the dynamics of the tumor environment, offering a tailored therapeutic approach that is not possible with conventional external production methods. 3. Localized Production at Tumor Sites: • Novelty: Producing antigens directly at the tumor site is a novel concept that contrasts sharply with traditional methods where antigens are administered systemically or near the body’s surface. By focusing antigen production precisely where it is needed, implantable systems can enhance the local immune response and improve therapeutic efficacy. • Inventiveness: The inventive nature is evident in the way these systems integrate with the tumor microenvironment, potentially improving antigen uptake by immune cells and promoting a more targeted immune response. This localized approach can lead to better tumor recognition and destruction, addressing limitations of systemic or surface-based antigen delivery methods. 4. Integration of Multiple Functions: • Novelty: The integration of multiple functions within a single implantable system—such as antigen production, immune modulation, and continuous release—represents a novel advancement. Existing technologies typically separate these functions into different devices or treatment stages, leading to fragmented therapeutic approaches. • Inventiveness: The inventive aspect is found in the multi-functional capabilities of these systems. For example, combining antigen production with immunostimulatory agent delivery or gene therapy within the same device allows for a synergistic effect that enhances overall treatment outcomes. This integrated approach provides a more comprehensive solution compared to traditional methods. 5. Personalized and Adaptive Therapy: • Novelty: The ability of implantable systems to offer personalized and adaptive therapy based on individual patient characteristics and tumor dynamics is a novel feature. Current treatments often use standardized antigen formulations and delivery schedules, which may not account for individual variations in tumor biology or patient response. • Inventiveness: The inventive nature of personalized and adaptive implantable systems lies in their ability to tailor antigen types, release rates, and therapeutic strategies to each patient’s unique needs. This customization enhances therapeutic effectiveness and minimizes adverse effects, representing a significant improvement over one-size-fits-all approaches. 6. Enhanced Safety and Reduced Risks: • Novelty: By producing and delivering antigens directly within the body, implantable systems reduce risks associated with external antigen handling, such as contamination and degradation. This approach is not commonly implemented in current therapies. • Inventiveness: The inventiveness is in how these systems address safety concerns by minimizing the handling and transportation of sensitive materials, thus reducing potential contamination and ensuring the stability of antigens. Additionally, localized production reduces systemic side effects and avoids issues related to external antigen delivery methods. In summary, the novelty and inventiveness of implantable antigen production systems he in their ability to produce antigens in situ, control and sustain antigen release, localize production at tumor sites, integrate multiple functions, offer personalized therapy, and enhance safety. These advancements represent a significant departure from current state-of-the-art methods, providing innovative solutions to existing challenges in cancer immunotherapy. Whilst the materials of construction of each of the layers are extensively discussed it will be apparent to the person skilled in the art that a wide range of polymeric and non-polymeric materials that may be biodegradable, bioresorbable or inert such that they may remain in the body, may be used. Furthermore the pore sizes for conduits for material transfer from one chamber to another will also be obvious as well as the rate controlling pores for the transfer of antigens or antigen coding gene carrying vectors to be released into the local environment, whereby the pores may surround partially or fully the outer surfaces or adjoining chambers, and pore sizes may be equal to or at least twice the diameter of the material that is diffusing or travelling through the pores or conduits, or several fold larger in diameter, but with a lower number of pores, to control the rate of release. Release of antigens or antigen coding material may be through the osmotic gradient created, or by compression of the chambers resulting from the absorption of moisture from the surrounding environment. Alternatively it may occur as the outer casing gradually erodes in-situ as previously highlighted. It will be appreciated that the numerous features described above and / or illustrated herein are set forth by way of example and are not intended to limit the scope of the invention. Numerous alternatives, variations, modifications, additions, and omissions, to those examples will be apparent to a skilled person in the relevant art. It is envisaged that features from different embodiments may be brought together, without adding to the scope of the invention. In addition, the order of any features in the form of method steps or sequences in the description, claims and / or drawings herein is not intended to require that order of performance unless a particular order is necessary for technical reasons. Multiple features in a single claim herein may be so combined in that claim for, for example, fiscal, not technical reasons and so such combined features are not necessarily intended to form a whole inseparable technical concept. Thereby, in the claims set forth, it is intended that claim features may be exchanged between, or extracted from, claims containing other features without broadening the scope of the invention, or causing a so-called intermediate generalisation.

Claims

1. An implantable device for in vivo delivery of one or more tumor-specific antigens within a patient, the device being configured to release said tumor-specific antigen(s) locally, wherein the device is configured to autonomously produce said tumor-specific antigens in situ via integrated antigen-producing components, and to sustain antigen release overtime.

2. The device of claim 1, wherein the antigen-producing components comprise live cells selected from: engineered allogeneic tumor cells, autologous dendritic cells loaded with tumor antigens, or CRISPR-engineered cells.

3. The device of claim 1, wherein the device comprises a microchip with MEMS-controlled reservoirs and microfluidic channels for programmable release of antigen or antigen-encoding nucleic acids.

4. The device of claim 1, wherein the device includes a hydrogel matrix encapsulating antigens and regulating their diffusion kinetics via stimuli-responsive linkages, wherein said linkages are pH-cleavable, enzyme-cleavable, or ROS-cleavable.

5. The device of claim 1, wherein the device is configured to co-release immunostimulatory adjuvants selected from CpG oligonucleotides, GM-CSF, or cytokines alongside said tumor-specific antigens.

6. The device of claim 1, wherein the device is configured to co-release immune checkpoint inhibitors selected from anti-PD-1 or anti-PD-Ll antibodies.

7. The device of claim 1, wherein the device comprises a barrier layer configured to prevent systemic release of antigens above a threshold concentration, thereby reducing the risk of cytokine storm.

8. The device of claim 1, wherein the device is biodegradable and configured to be fully resorbed within 3-6 months post-implantation.

9. The device of claim 1, wherein the device is pre-loaded with patient-derived tumor material.

10. The system of claim 4, wherein the one or more biosensors are capable of wirelessly transmitting data to an external monitor.

11. The device of claim 1, wherein the device includes MRI-visible markers comprising Gd3+ or iron oxide for monitoring device location and degradation.

12. A system for treating metastatic cancer, comprising:a plurality of implantable devices according to claim 1, wherein each device is configured for deployment at a different anatomical site, and wherein the devices are configured to provide a coordinated, distributed release of tumor-specific antigens.

13. A kit for preparing a cancer immunotherapy device, comprising:(a) an implantable device according to claim 1;(b) a modular cartridge containing patient-specific antigen-producing components; and(c) instructions for aseptically loading the cartridge into the device prior to implantation.

14. The device of claim 1 for use in a method of neoadjuvant therapy prior to surgical resection of a tumor.

15. The device of claim 1 for use in a method of prophylactic vaccination in a high-risk patient.

16. The device of claim 1 for use in veterinary medicine for treatment of tumors in a nonhuman mammal.

17. An implantable antigen-delivery apparatus, comprising:a biocompatible structure housing antigen-producing components, wherein the apparatus is configured to integrate with the tumor microenvironment and stimulate localized immune activation, wherein the antigen-producing components comprise live cells engineered to secrete tumor-specific antigens, and wherein the apparatus comprises a controlled release mechanism configured to permit sustained diffusion of said antigens while retaining said live cells.

18. The system of claim 17, wherein the implantable device comprises a tumour tissue processing unit configured to apply mechanical lysis or controlled thermal energy to patient-derived tumor tissue to generate antigenic cell fragments in situ.

19. A system for personalized cancer immunotherapy, comprising: an implantable device configured to generate tumor-specific antigens in situ, wherein the device is pre-loaded with antigen-producing components derived from or specifically matched to the patient's tumor mutational profile.

20. A system for cancer immunotherapy, comprising:an implantable device configured to generate tumor-specific antigens in situ, wherein the device includes one or more biosensors configured to monitor a local physiological marker selected from cytokines, metabolites, pH, or enzymatic activity, and wherein antigen release is modulated in a closed-loop manner based on signals from said biosensors.

21. A method for eliciting an immune response against a tumor, comprising: implanting a device in a patient that autonomously produces and releases tumor-specific antigens in situ, wherein said antigens are patient-specific neoantigens, and wherein the device is configured to sustain antigen release over time to promote continuous immune recognition and attack of the tumor.T +44(0)30 0300 2000A

Images